By Brian Kiprono - Reporter
Kenya, 1 September 2026 - Kenya has struck a deal with pharmaceutical giant Pfizer that could sharply reduce the cost of medicines used to treat nine types of cancer, potentially easing one of the biggest barriers facing patients: the price of treatment.
Under the agreement between Pfizer and the Kenya Medical Supplies Authority (KEMSA), made through Pfizer’s Accord for a Healthier World, the prices of medicines for breast, stomach, colon, lung, prostate and oesophageal cancers, as well as leukaemia, lymphoma and multiple myeloma, are expected to fall by more than sevenfold.
President William Ruto described the agreement as a “consequential agreement”, saying that in some cases the cost of a medicine could fall from as much as KSh 1 million to below KSh 50,000 per treatment cycle. He also said the reduced prices would make the KSh 800,000 Social Health Authority (SHA) cancer package adequate to cover treatment without patients having to make additional payments.
That could represent a significant change for Kenyan families who have traditionally had to make difficult choices between paying for cancer treatment and meeting basic household needs. But the significance of the deal is not simply the size of the price reduction announced by the government. Its real test will be whether the cheaper medicines are consistently available to patients, covered through SHA when they need them, and delivered through a health system capable of getting patients diagnosed and treated early.
The price of cancer is more than the price of medicine#
The announcement comes at a time when Kenya's cancer burden is becoming increasingly difficult to ignore.
Data released by the National Cancer Institute of Kenya in 2025 showed that the country was recording more than 44,000 new cancer diagnoses annually, with more than 29,000 deaths each year. The institute said cancer had overtaken cardiovascular disease to become Kenya's second leading cause of death, behind infectious diseases.
The numbers give the Pfizer-KEMSA agreement a significance beyond a pharmaceutical price cut. Thousands of Kenyans enter the cancer treatment system every year, but many encounter a combination of expensive medicines, diagnostic delays, shortages and the cost of travelling to treatment centres.
A recent review of 60 studies on the economic burden of cancer care in Kenya, covering research published between 2018 and May 2025, found that the cost of treatment remains a “major barrier.” In public hospitals, treatment for stage I to III breast and cervical cancer was estimated at about Sh173,288 to Sh199,152, while the same treatment in private facilities could cost between approximately Sh970,000 and Sh1.5 million.
The review also found that annual out-of-pocket cancer expenditure in some cases reached nearly Sh1.64 million, pushing many households into what researchers classify as catastrophic health expenditure.
For some patients, the financial pressure eventually becomes a choice between continuing treatment and protecting the family's ability to survive financially. One study included in the review found that 53.8 per cent of breast cancer patients discontinued treatment because of cost, while 73 per cent of respondents in another study reported selling assets to cope with cancer-related expenses.
This is the context in which a reduction from hundreds of thousands of shillings, or, in some cases, around Sh1 million, to below Sh50,000 per cycle becomes potentially transformative.
But it is also why the price announced by the government should not be mistaken for the total cost of cancer care.
A cheaper drug does not necessarily mean cheaper cancer care#
Cancer treatment is rarely limited to the medicine itself. Patients may need biopsies, imaging, laboratory tests, consultations, surgery, radiotherapy, chemotherapy, supportive medicines, transport and repeated hospital visits. For patients living outside major urban centres, travelling to an oncology facility can add another layer of expense.
The recent review found that essential cancer medicines were available in fewer than half of public health facilities, with availability for a selected group of 24 essential medicines standing at about 44 per cent. Stock-outs were linked in part to procurement delays, sometimes lasting several months.
That raises one of the most important questions surrounding the new Pfizer agreement: Will the reduced-price medicines be available when patients need them?
A medicine that costs Sh50,000 on paper but is unavailable at a public hospital may offer little relief to a patient who must buy it elsewhere at a higher price.
The Pfizer agreement therefore addresses one part of the affordability problem, medicine pricing, but the wider cancer-care chain will determine how much patients ultimately benefit.
What patients stand to gain#
According to President Ruto, the agreement covers medicines used in the treatment of nine cancers:
● breast cancer;
● stomach cancer;
● colon cancer;
● lung cancer;
● prostate cancer;
● oesophageal cancer;
● leukaemia;
● lymphoma; and
● multiple myeloma.
The government says the price reductions will be more than sevenfold, with some treatments falling from as much as Sh1 million to less than Sh50,000 per cycle.
The President further said the agreement would allow patients to access “newer medicines” without the “10-year wait" that he said currently affects the arrival of breakthrough cancer treatments in Kenya.
If implemented as described, this could be particularly important for patients who have exhausted older treatment options or require newer therapies.
There is also a longer-term ambition attached to the agreement. Ruto, who serves as the African Union Champion for Local Manufacturing of Medical Commodities, said Pfizer would make technologies and newer medicines available for pharmaceutical production in Africa.
That could eventually move the conversation beyond importing cheaper medicines towards strengthening local pharmaceutical manufacturing and improving the continent's ability to produce essential medical commodities.
But when will patients actually feel the difference?#
This is one of the areas that remains unclear from the information released so far.
The announcement establishes the agreement and the scale of the price reductions, but patients will want to know when the new prices take effect, which specific medicines and formulations are covered, which facilities will stock them, and how the purchasing and reimbursement process under SHA will work in practice. These details matter.
For a cancer patient already in treatment, the difference between an agreement announced today and a medicine available at a hospital tomorrow can be enormous.
The government has said the new prices will make the Sh800,000 SHA cancer package “fully adequate” without additional costs to patients.” However, the evidence available also shows that Kenya's health financing reforms are still being tested.
A 2026 review of the cancer-care evidence, published in ecancermedicalscience, found that only two of the 60 studies examined the post-2023 SHA system, meaning there is still limited evidence on how effectively the new system is working specifically for cancer patients. That makes implementation one of the most important parts of the Pfizer deal to watch.
The deal comes after another Pfizer investment in Kenya#
More from Kenya
The latest agreement is also not Pfizer's first major cancer-related intervention in Kenya this year.
In January, The Pfizer Foundation announced a three-year, $10 million investment through its Action & Impact: A Cancer Care Initiative to expand access to breast cancer diagnosis, treatment and care in Kenya and Ethiopia.
In Kenya, the programme is being implemented through the Academic Model Providing Access to Healthcare (AMPATH), with an emphasis on improving early diagnosis, treatment and patient navigation.
The initiative includes efforts to strengthen diagnostic systems, including digital pathology, tumour registries, biobanking, clinical breast examinations, ultrasound services and systems to help patients navigate the cancer-care process.
Pfizer said at the time that the investment was intended to address disparities in breast cancer outcomes between high-income countries and sub-Saharan Africa, where survival rates remain significantly lower.
This is important because lowering the price of treatment does not solve the problem if patients reach treatment too late.
Early diagnosis remains critical#
Kenya's cancer burden is not driven by treatment costs alone.
NCIK chief executive Dr Elias Melly has warned about a range of factors contributing to the country's cancer burden, including exposure to carcinogenic chemicals and gaps in the healthcare system.
The evidence provided to the national cancer debate also points to late diagnosis as a major problem. Across studies reviewed in the recent assessment of cancer care in Kenya, roughly seven in 10 patients were diagnosed at stage III or IV.
Late diagnosis can make treatment more complicated, more expensive and less effective.
This means that a successful cancer strategy needs to connect the pieces: prevention, awareness, screening, diagnosis, affordable medicines, specialist care, radiotherapy, surgery, palliative care and follow-up.
Dr Melly says that Cancer cannot be treated “entirely unless our healthcare system is fixed.”
That warning is particularly relevant to the Pfizer agreement. A cheaper treatment can only save lives if patients can reach a facility, receive an accurate diagnosis, find the medicine in stock and afford the other components of their care.
The human cost behind the statistics#
For families confronting cancer, these questions are not abstract.
Dr Timothy Olweny, chairperson of the NCIK Board of Trustees, has repeatedly highlighted the financial burden carried by cancer patients and their families. He has also warned about the amount of money some families spend towards the final stages of life.
“We have to engage our patients, I am passionate about ‘end of life care’ because a lot of people spend most of their finances, more than 90 per cent, in the last two weeks of their lives,” Dr Olweny said in 2025.
His point exposes another dimension of the cancer-cost debate: affordability is not simply about extending treatment but ensuring that patients receive care that improves their quality of life and respects their choices.
For survivors, meanwhile, the journey can involve years of treatment and financial uncertainty.
Mercy Osoro, a lymphoma survivor who was diagnosed as a child, described to Nation Media undergoing chemotherapy, suffering a recurrence and later developing heart failure linked to treatment. Yet she remains a survivor and has used her experience to encourage others not to lose hope.
“I am still standing here as a survivor with scars just to tell other cancer patients that there is hope,” she told Nation
Her experience also illustrates why access to affordable medicine must be accompanied by safe, continuous and properly managed cancer care.
What remains unclear#
The Pfizer-KEMSA agreement is significant, but several practical questions remain unanswered.
First, when exactly will the reduced prices become available to patients? The announcement gives the scale of the reduction but does not specify a detailed implementation schedule.
Second, which specific Pfizer medicines and strengths are covered? Saying that nine cancer types are included does not tell patients which drugs, treatment lines or formulations they can expect to access at the reduced price.
Third, where will the medicines be available? The effectiveness of the agreement will depend heavily on procurement, distribution and stock management through KEMSA and health facilities.
Fourth, how will SHA reimbursements work in practice? The government says the Sh800,000 cancer package will be sufficient under the new prices, but patients will ultimately judge the agreement by what they are asked to pay at the hospital.
Fifth, will the lower prices remain sustainable? A durable reduction in the cost of cancer medicines requires reliable procurement and financing rather than a one-off intervention.
And finally, will cheaper medicines reach patients early enough to change outcomes?
That last question may ultimately determine the true impact of the agreement.
A potentially important shift#
The Pfizer-KEMSA deal arrives at a critical moment for Kenya's cancer response.
For a patient facing a medicine bill of hundreds of thousands of shillings, a reduction to below Sh50,000 per cycle could mean the difference between delaying treatment and starting it. For a family that has already sold property, borrowed money or organised community fundraisers, the reduction could ease a devastating financial burden. But Kenya's cancer crisis is larger than the price of a medicine.
The country is recording tens of thousands of new cases every year. Many patients are diagnosed late. Essential medicines are not consistently available in public facilities. Health workers and specialist services remain unevenly distributed, while patients outside major cities face additional transport and access barriers.
The Pfizer agreement therefore offers a potentially important piece of the solution, but its success will depend on what happens after the announcement.
The question for patients is no longer only whether cancer medicines can become cheaper. It is whether the cheaper medicines will arrive, remain in stock, be covered by SHA, and reach patients early enough to make a difference. That is where the promise of the agreement will ultimately be tested.